Related by context. All words. (Click for frequent words.) 73 myelodysplastic syndromes 70 leukemia AML 70 myelodysplastic syndrome MDS 68 refractory chronic lymphocytic 67 hematologic disorders 67 Acute Myeloid Leukemia AML 66 cell lymphoma CTCL 66 chronic lymphocytic leukemia CLL 66 azacitidine 65 B CLL 65 metastatic renal cell carcinoma 65 cell chronic lymphocytic 65 acute myelogenous leukemia AML 65 non metastatic osteosarcoma 65 IV NSCLC 65 grade cervical intraepithelial 64 Xanafide 64 grade glioma 64 aplastic anemia AA 64 myeloproliferative diseases 64 leukemia CLL 64 leukemia ALL 64 Myelofibrosis 64 myeloproliferative disorders 64 myelofibrosis 64 lupus nephritis 64 recurrent NSCLC 64 Amrubicin 64 acute myeloid leukemia AML 64 docetaxel Taxotere R 64 cytopenias 64 HER2 positive metastatic breast 63 relapsed refractory multiple myeloma 63 CTAP# Capsules 63 romiplostim 63 Hodgkin lymphoma NHL 63 Ceflatonin 63 Follicular Lymphoma 63 mRCC 63 Nilotinib 63 homozygous familial hypercholesterolemia 63 relapsed SCLC 63 refractory multiple myeloma 63 Plicera 63 hyperphenylalaninemia HPA due 63 TNF antagonist 63 Cloretazine 63 metastatic gastric 63 TELINTRA 63 chronic eosinophilic leukemia 63 lymphoma CTCL 63 Cutaneous T 63 efalizumab 63 invasive candidiasis 63 hematologic toxicity 63 relapsed ovarian cancer 63 refractory acute myeloid 63 essential thrombocythemia 63 non splenectomized 63 PEGylated interferon beta 1a 63 stage IIIB 63 grade cervical dysplasia 63 Myelodysplastic syndromes MDS 63 ara C 63 Amigal 62 Dasatinib 62 pancreatic NET 62 prostate cancer CRPC 62 myelodysplastic myeloproliferative diseases 62 Fludarabine 62 unfavorable cytogenetics 62 paroxysmal nocturnal hemoglobinuria PNH 62 HCV genotype 62 Omacetaxine 62 hypoparathyroidism 62 dasatinib Sprycel ® 62 Dacogen injection 62 neutropenia dehydration dyspnea 62 cutaneous T 62 erlotinib Tarceva ® 62 idiopathic thrombocytopenic purpura ITP 62 phase IIb clinical 62 acute GvHD 62 purpura ITP 62 recurrent ovarian cancer 62 aHUS 62 myelofibrosis polycythemia vera 62 RoACTEMRA 62 AAT deficiency 62 hepatocellular carcinoma HCC 62 refractory cutaneous T 62 nephrotoxicity 62 posterior uveitis 62 Annamycin 62 TTF Therapy 62 severe neutropenia 62 complement inhibitor eculizumab 62 sodium thiosulfate STS 62 recurrent glioblastoma multiforme 62 axitinib 62 Acute Myelogenous Leukemia AML 62 MYLOTARG 62 generation purine nucleoside 62 familial amyloidotic polyneuropathy FAP 62 histologies 62 soft tissue sarcomas 62 investigational monoclonal antibody 62 HeFH 61 tanespimycin 61 chronic ITP 61 Hodgkin lymphoma HL 61 Vidaza azacitidine 61 forodesine 61 Metastatic Colorectal Cancer 61 pediatric acute lymphoblastic 61 metastatic malignant 61 Acute Myeloid Leukemia 61 leukemia APL 61 Vidaza ® 61 Lenalidomide 61 mildly symptomatic 61 relapsing multiple sclerosis 61 Toxicities 61 myeloproliferative neoplasms 61 inhibitor RG# 61 secondary hyperparathyroidism 61 relapsed MM 61 SPRYCEL ® 61 potentially hepatotoxic 61 myelodysplastic syndrome 61 haematological malignancies 61 deletion 5q 61 esophageal candidiasis 61 lintuzumab SGN 61 dose cytarabine 61 decitabine 61 Phenoptin 61 Voreloxin 61 Torisel 61 atypical hemolytic uremic syndrome 61 hypercalcemia 61 INCB# [003] 61 temsirolimus 61 sodium glucose cotransporter 61 CYT# potent vascular disrupting 61 alfa 2a 61 imatinib Gleevec ® 61 refractory gout 61 Pivotal Phase 61 Letairis ambrisentan 61 clofarabine 61 plus COPEGUS 61 squalamine 61 novel VDA molecule 61 Relapsed Refractory 61 docetaxel Taxotere ® 61 efaproxiral 61 unresectable 61 adecatumumab 61 fallopian tube carcinoma 61 advanced hepatocellular carcinoma 61 registrational trial 61 Fludara ® 61 grade gliomas 61 pheochromocytoma 61 severe oral mucositis 61 STRIDE PD 61 Clofarabine 61 atherothrombotic events 61 ribavirin therapy 61 interferon gamma 1b 61 atypical Hemolytic Uremic Syndrome 61 BARACLUDE ® 61 Chronic Myeloid Leukemia 61 chronic idiopathic thrombocytopenic purpura 61 hematologic malignancies 61 metastatic CRC 61 metastatic GIST 61 invasive fungal infections 61 K ras mutations 61 castration resistant prostate cancer 61 SJIA 61 primary hypercholesterolemia 61 alvespimycin 61 pralatrexate 60 TORISEL 60 renal cell carcinoma 60 bevacizumab Avastin ® 60 serologically active systemic lupus 60 sorafenib Nexavar 60 Tarceva TM 60 Evoltra ® 60 gastrointestinal stromal tumors 60 riociguat 60 hormone refractory prostate cancer 60 refractory Hodgkin lymphoma 60 multiple myeloma MM 60 gastrointestinal stromal tumor GIST 60 recurrent glioma 60 AEG# 60 hematologic cancers 60 Uricase PEG 60 posaconazole 60 haematologic malignancies 60 lomitapide 60 tuberous sclerosis TS 60 hematological malignancies 60 dirucotide 60 trabectedin 60 Ribavirin causes 60 MAGE A3 ASCI 60 depsipeptide 60 hematological malignancy 60 HoFH 60 elotuzumab 60 INCB# [001] 60 papillary renal cell carcinoma 60 chronic myeloid 60 colorectal carcinoma 60 Philadelphia Chromosome Positive 60 LymphoStat B 60 refractory NSCLC 60 HCV genotypes 60 elacytarabine 60 gefitinib Iressa 60 systemic juvenile idiopathic 60 Azacitidine 60 metastatic malignant melanoma 60 Oral Fingolimod 60 cetuximab Erbitux R 60 Dacogen decitabine 60 tumor lysis syndrome 60 relapsed multiple myeloma 60 placebo controlled Phase 60 non squamous 60 systemic lupus erythematosus SLE 60 Tasimelteon 60 subependymal giant cell 60 standard chemotherapy regimens 60 medullary thyroid cancer 60 epithelial tumors 60 YONDELIS 60 PNH patients 60 hematological cancers 60 PNP inhibitor 60 non squamous NSCLC 60 hepatocellular cancer 60 LymphoStat B belimumab 60 systemic anaplastic large 60 Myelodysplastic syndromes 60 unresectable stage 60 corticosteroid dexamethasone 60 IV melanoma 60 myelosuppression 60 relapsing remitting MS RRMS 60 Ceflatonin R 60 relapsed Acute Myeloid 60 Alemtuzumab 60 NAGS deficiency 60 LHRH receptor positive 60 mixed hyperlipidemia 60 REVLIMID lenalidomide 60 cutaneous T cell 60 heavily pretreated 60 glufosfamide 60 gastric carcinoma 60 essential thrombocythemia ET 60 refractory indolent non 60 R lenalidomide 60 Campath alemtuzumab 60 AVONEX ® 60 acute coronary syndromes ACS 60 castrate resistant prostate cancer 60 opioid induced constipation OIC 60 Hormone Refractory Prostate Cancer 60 paclitaxel Taxol ® 60 smoldering myeloma 60 Hepatocellular Carcinoma HCC 60 systemic ALCL 60 phase IIb trial 60 Peginterferon alfa 2b 60 Chronic lymphocytic leukemia CLL 60 Myelodysplastic Syndrome MDS 60 fluvastatin 60 histone deacetylase HDAC inhibitor 60 taxane chemotherapy 60 gemcitabine chemotherapy 60 systemic lupus erythematosus 60 terlipressin 60 Navelbine ® 60 docetaxel chemotherapy 60 vandetanib 60 FOLFOX6 chemotherapy regimen 60 Bezielle 60 erythematosus 60 Randomized Phase 60 CMV disease 60 rALLy clinical trial 60 chronic granulomatous disease 60 SHPT 60 paroxysmal nocturnal hemoglobinuria 59 eltrombopag 59 chemotherapy induced neutropenia 59 vinorelbine 59 VELCADE melphalan 59 Nexavar sorafenib 59 International Prognostic Scoring 59 HuMax EGFr 59 HuLuc# 59 metaglidasen 59 erythematosus SLE 59 metastatic castration resistant 59 Telintra 59 pegylated interferons 59 PREZISTA r 59 Erlotinib 59 tumors GIST 59 imatinib resistant 59 gemcitabine Gemzar ® 59 FOLOTYN ® 59 Peginterferon 59 R sorafenib tablets 59 gastrointestinal mucositis 59 tiuxetan 59 HuMax CD4 59 autoantibody positive 59 CCR5 tropic HIV 59 Alocrest 59 familial hypercholesterolemia 59 Bronchiectasis 59 Myelodysplastic Syndromes MDS 59 amrubicin 59 refractory AML 59 polycythemia vera essential thrombocythemia 59 alpha interferons 59 hypereosinophilic syndrome 59 gemcitabine carboplatin 59 urothelial bladder cancer 59 sorafenib tablets 59 familial hypercholesterolemia FH 59 cancer mCRC 59 PRT# 59 recurrent glioblastoma 59 Atypical Hemolytic Uremic Syndrome 59 bendamustine 59 Mantle Cell Lymphoma 59 HBeAg negative 59 Natalizumab 59 haematologic 59 nonsmall cell lung cancer 59 ganetespib 59 gastrointestinal stromal tumor 59 bladder carcinoma 59 acute leukemias 59 dasatinib Sprycel 59 CLL SLL 59 malignant pleural mesothelioma 59 Romiplostim 59 metastatic colorectal cancer 59 low dose cytarabine 59 FOLFIRI 59 metastatic RCC 59 Pegasys ® 59 HRPC 59 ocrelizumab 59 candidemia 59 HGS ETR1 59 System IPSS 59 custirsen 59 Neutropenia 59 vWD 59 PRTX 59 Myelodysplastic Syndrome 59 PXD# 59 Pivotal Phase III 59 VIDAZA 59 Clolar ® 59 metastatic renal cell 59 unstable angina UA 59 severe malignant osteopetrosis 59 diabetic neuropathic pain 59 Acute Myeloid Leukaemia AML 59 dasatinib 59 chronic immune thrombocytopenic 59 sJIA 59 AA Amyloidosis 59 Gleevec resistant 59 valsartan amlodipine 59 stage IIIb 59 tocilizumab 59 Aplidin 59 Li Fraumeni Syndrome 59 Diffuse Large B 59 juvenile idiopathic arthritis JIA 59 MYCN amplification 59 Cloretazine ® 59 alkylating agents 59 metastatic neuroendocrine tumors 59 induced macular edema 59 pan HDAC inhibitor 59 primary immunodeficiency PI 59 ancrod 59 rheumatoid arthritis psoriatic arthritis 59 nucleoside analog 59 Chronic Lymphocytic Leukemia 59 heparin induced thrombocytopenia 59 platinum refractory 59 nilotinib 59 ribavirin RBV 59 infusional 5-FU/LV 59 acute myeloid 59 HSCT 59 IMiDs 59 EGFR TKI 59 pancytopenia 59 Janus kinase 59 advanced NSCLC 59 AVASTIN 59 talactoferrin 59 ® lenalidomide 59 mg/m2 dose 59 relapsed leukemia 59 R #Y ibritumomab 59 proliferative diabetic retinopathy 59 HGS ETR2 59 adverse cytogenetics 59 Vicinium TM 59 Epratuzumab 59 follicular lymphoma FL 59 Vidaza R 59 platelet inhibitor 59 carcinoid syndrome 59 sunitinib malate 59 lintuzumab 59 interferon alfa 2b 59 untreated AML 59 small lymphocytic lymphoma 59 severe hypercholesterolemia 59 prostate pancreatic 59 5-fluorouracil/leucovorin 59 castration resistant 59 Myelodysplasia 59 rapid virologic response 59 radiochemotherapy 59 hepatocellular carcinomas 59 Fibrillex TM 59 denileukin diftitox 59 ACTEMRA TM 59 azacytidine 58 post herpetic neuralgia PHN 58 BR.# 58 hepatitis C HCV 58 radiation sensitizer 58 mCRC patients 58 sorafenib Nexavar ® 58 Granulocyte Colony Stimulating Factor 58 Ceflatonin ® 58 untreated de novo 58 Hepsera adefovir dipivoxil 58 MGd 58 stage IIIb IV 58 daunorubicin 58 pulmonary exacerbations 58 peripheral sensory neuropathy 58 imetelstat 58 thalidomide Thalomid 58 teriflunomide 58 Juvenile Idiopathic Arthritis 58 haematopoietic stem cell 58 advanced metastatic renal 58 evaluating REVLIMID 58 hypercholesterolemic patients 58 Chronic lymphocytic leukemia 58 Vidaza 58 receptor tyrosine kinase inhibitor 58 sunitinib 58 taxane therapy 58 Hsp# inhibition 58 Naive Patients 58 A1PI 58 EGFR mutation positive 58 basal cell carcinoma BCC 58 LUX Lung 58 retinal vein occlusion 58 hepatic impairment 58 transplantation HCT 58 liposomal formulation 58 Severe Primary IGFD 58 dacarbazine 58 Azedra 58 pancreatic insufficiency 58 MPS VI 58 pertuzumab 58 NYHA Class II 58 LHRH antagonists 58 cervical intraepithelial neoplasia 58 ISIS # 58 vascular disrupting agent 58 elevated triglyceride levels 58 antibody MAb 58 dirucotide MBP# 58 Hsp# Inhibitor 58 five MDS subtypes 58 Ophena TM 58 GW# [003] 58 relapsed refractory 58 cyclophosphamide FC 58 bexarotene 58 metastatic castrate resistant 58 immune thrombocytopenic purpura ITP 58 pegfilgrastim 58 GvHD 58 Orphan Drug status 58 splenectomized 58 cytotoxic chemotherapy 58 cinacalcet 58 urocortin 2 58 pain palliation 58 Zevalin R Ibritumomab 58 APOPTONE 58 Personalized Immunotherapy 58 refractory CTCL 58 dose escalation Phase 58 Glufosfamide 58 MELAS 58 vemurafenib 58 Vitaxin 58 gastrointestinal stromal tumors GIST 58 cilengitide 58 myeloproliferative 58 GAMMAGARD 58 carcinoid tumors 58 Virulizin ® 58 HCV SPRINT 58 interferon therapy 58 including eniluracil ADH 58 antitumor activity 58 Doxil ® 58 Multiple Myeloma MM 58 anemia neutropenia 58 ATTR 58 Heterozygous Familial Hypercholesterolemia 58 OHR/AVR# 58 MDS MPD 58 PEGINTRON TM 58 Complicated Skin 58 hypercholesterolemia 58 oral ridaforolimus 58 formerly LymphoStat B 58 Kit CD# positive 58 stage IIIA 58 Phase #/#a trial 58 idiopathic thrombocytopenic purpura 58 AAT Deficiency 58 adriamycin 58 IMA# 58 refractory CLL 58 PEG IFN 58 Peginterferon Alfa 2a 58 heterozygous FH 58 ruxolitinib 58 bortezomib Velcade R 58 symptomatic neurogenic orthostatic hypotension 58 remission induction 58 Pharmacokinetics PK 58 predominantly classic subfoveal 58 neratinib 58 interferon IFN 58 rALLy 58 maribavir 58 relapsing remitting multiple sclerosis 58 metastatic colorectal carcinoma 58 NSCLC 58 Denufosol 58 seliciclib 58 Rasilez Tekturna 58 BAY #-# 58 homozygous FH 58 metastatic kidney 58 untreated multiple myeloma 58 neurogenic orthostatic hypotension 58 Cinryze TM 58 Tavocept 58 mifamurtide 58 Advanced Renal Cell 58 cardiotoxicity 58 Pralatrexate 58 TNF Tumor Necrosis Factor 58 Mitoxantrone 58 renal dysfunction 58 brivaracetam 58 EGFR expressing mCRC 58 demethylating agent 58 Kepivance 58 adult chronic ITP 58 metastatic hormone refractory 58 Bortezomib 58 BENLYSTA ® 58 locoregional recurrence 58 palifermin 58 Critical Limb Ischemia CLI 58 taxane resistant 58 chronic myocardial ischemia 58 chronic HBV 58 decompensated liver disease 58 systemic fungal infections 58 histologically confirmed 58 ABCB1 58 APTIVUS 58 PEGylated anti 58 IMiDs ® compound 58 Brentuximab Vedotin SGN 58 glioblastoma multiforme GBM 58 LymphoStat B TM 58 Elitek 58 taxane refractory 58 smoldering multiple myeloma 58 allogeneic transplantation 58 Zerenex 58 von Willebrand disease 58 idiopathic pulmonary fibrosis IPF 58 oral prodrug 58 TRISENOX 58 Gleevec imatinib mesylate 58 Enzyme Replacement Therapy 58 kidney urologic 58 baminercept 58 gemcitabine Gemzar 58 hepatocellular carcinoma 58 p# biomarker 58 pulmonary hypertension PH 58 pancreatic adenocarcinoma 58 Insegia 58 Tamibarotene 58 OPAXIO 58 carcinoma mCRC 58 luteinizing hormone releasing 58 HIV HCV coinfected 58 metastatic HRPC 58 metastatic bladder 58 catheter occlusion 58 protease inhibitor PI 58 Genasense ® oblimersen 58 Troxatyl 58 cholangiocarcinoma 58 Tanespimycin 58 NOMID 58 Pemetrexed 58 Phase Ib study 58 Major Depressive Disorder MDD 58 IL# PE#QQR 58 Paraplatin ® carboplatin 58 PEG PAL 58 hyperphosphatemia 58 colesevelam HCl 58 IRESSA 58 JAK2 inhibitor 58 TTR amyloidosis 57 alpha folate receptor 57 pulmonary arterial hypertension 57 geographic atrophy 57 fluoropyrimidine 57 del 5q 57 ZACTIMA 57 TYZEKA 57 alkylating agent 57 Vidofludimus 57 Allovectin 7 ® 57 chemotherapeutic agent 57 epithelial ovarian 57 dacarbazine DTIC 57 Neoadjuvant 57 myopathy rhabdomyolysis 57 EGFR HER2 57 solid tumors 57 unresectable hepatocellular carcinoma HCC 57 peptibody 57 transthyretin TTR mediated amyloidosis 57 prostate adenocarcinoma 57 neuroendocrine tumors 57 Sorafenib 57 CMV infection 57 Tiuxetan 57 monoclonal antibody conjugated 57 zanolimumab 57 adrenocortical cancer 57 virological response 57 Forodesine HCl 57 ISTODAX 57 PAOD 57 recurrent colorectal cancer 57 Chronic Lymphocytic Leukemia CLL 57 myeloproliferative disorder 57 nasopharyngeal carcinoma 57 clazosentan 57 febrile neutropenia 57 evaluating tivozanib 57 gastrointestinal toxicities 57 voreloxin 57 Trastuzumab 57 novel synthetic PEGylated 57 velafermin 57 FOLFOX chemotherapy 57 bone marrow suppression 57 gastrointestinal stromal tumors GISTs 57 tumor recurrence 57 Dapagliflozin 57 anthracyclines taxanes 57 JAK1 57 colorectal cancer CRC 57 Pirfenidone 57 active ankylosing spondylitis 57 CIMZIA TM 57 carcinoma HCC 57 Amgen Neulasta R 57 Leukemias 57 TRO# 57 thromboembolic events 57 systemic lupus erythematosus psoriasis 57 AEGR 57 dose dexamethasone 57 Vandetanib 57 PROMACTA 57 unresectable recurrent 57 parathyroid carcinoma 57 AST ALT 57 hematopoietic cancers 57 RG# [001] 57 Safinamide 57 anti leukemic 57 Myelodysplastic Syndromes 57 CHOP chemotherapy 57 hA# 57 immunomodulatory therapy 57 Irinotecan 57 allogeneic stem cell 57 Lymphocytic 57 peripheral neuropathic pain 57 calcineurin inhibitors 57 MKC# MT 57 Morquio 57 prostate cancer HRPC 57 novel histone deacetylase 57 Lupus nephritis 57 hematological diseases 57 Metastatic Melanoma 57 ELACYT 57 galiximab 57 anthracycline containing 57 Leukine ® 57 GOUT 57 malignant ascites 57 peginterferon alfa 57 thrombocytopenic 57 varespladib 57 minimally symptomatic 57 REVLIMID R 57 lymphoma leukemia 57 IV metastatic melanoma 57 mycophenolate mofetil 57 Gleevec imatinib 57 RSR# 57 EGFR expressing 57 hydroxymethyl coenzyme 57 CTEPH 57 serum phosphate 57 mTOR kinase 57 histologic subtype 57 CIMZIA ™ 57 Taxotere docetaxel 57 Sym# 57 Aviptadil 57 methotrexate therapy 57 HNSCC 57 orally bioavailable 57 TACI Ig 57 interferon alfa 2a 57 invasive aspergillosis 57 metastatic renal 57 RGB # 57 TEMODAL 57 demonstrated antitumor activity 57 Mimpara 57 bortezomib Velcade 57 LHON 57 intracranial hemorrhage ICH 57 plus dexamethasone 57 cervical carcinoma 57 SNT MC# 57 Revlimid lenalidomide 57 cancer cachexia 57 cetuximab Erbitux 57 Carcinoid tumors 57 cell lymphoma ALCL 57 sustained virologic response 57 sapacitabine 57 bevacizumab Avastin 57 mCRC 57 squamous cell lung cancer 57 APPRAISE 57 romidepsin 57 Neulasta ® 57 KRAS status 57 Relapsing Remitting Multiple Sclerosis 57 Romidepsin 57 beta thalassemia 57 moderate renal impairment 57 cetuximab Erbitux ® 57 AA amyloidosis 57 nilotinib Tasigna ® 57 Cell Lymphoma 57 follicular NHL 57 lymphoid malignancies 57 neuroendocrine cancers 57 anthracycline therapy 57 pancreatic neuroendocrine tumors 57 rFVIIa 57 CML CP 57 Hereditary angioedema HAE 57 Orphan Drug designations 57 tyrosine kinase inhibitor TKI 57 juvenile idiopathic arthritis 57 xanthine oxidase inhibitor 57 ascending dose 57 zalutumumab 57 ASA# 57 Pegylated interferon 57 hypophosphatasia 57 resistant hormone refractory 57 hour bronchodilation 57 bevacizumab 57 cutaneous squamous cell carcinoma 57 chronic HCV infection 57 juvenile myelomonocytic leukemia 57 exocrine pancreatic insufficiency EPI 57 Genasense ® 57 unresectable locally advanced 57 chronic ITP patients 57 PROSTVAC VF 57 farletuzumab 57 HQK 57 Renal Cell Carcinoma RCC 57 potent CYP#A# inhibitors 57 Lung transplantation 57 cinacalcet HCl 57 superficial bladder cancer 57 KRAS mutations 57 metastatic colorectal 57 osteosarcoma Ewing sarcoma 57 IIIa inhibitor 57 Celgene Revlimid 57 chemotherapy cisplatin 57 tigecycline 57 leukemia multiple myeloma 57 goserelin 57 candesartan cilexetil 57 Estybon ™ 57 thrombocytopenia neutropenia 57 interferon alfa 57 myelofibrosis MF 57 HMG CoA reductase inhibitors 57 melphalan prednisone 57 HCV RESPOND 2 57 sarcomatoid 57 neovascular 57 visilizumab 57 advanced unresectable 57 5 FU leucovorin 57 EGFR inhibitors 57 Acute myeloid leukemia 57 demethylation agents 57 eculizumab 57 operable breast cancer 57 Eltrombopag 57 diagnosed Ph + 57 Solid Tumors 57 renal insufficiency 57 EOquin TM 57 weekly subcutaneous injections 57 TRAIL R1 57 hepatic metastases 57 biologic DMARD 57 delayed CINV 57 Mipomersen 57 herpetic keratitis 57 mycosis fungoides 57 Nexavar tablets 57 Copegus ribavirin 57 Campath ® 57 BrachySil TM 57 Combination REOLYSIN R 57 dose melphalan 57 anthracycline chemotherapy 57 virologic failure 57 myeloablative 57 vinca alkaloid 57 Ranolazine 57 sargramostim 57 Atacand 57 Archexin 57 Hepatocellular Carcinoma 57 Cloretazine R VNP#M 57 TRIOLEX HE# APOPTONE HE# 57 pediatric malignancies 57 dose limiting toxicities 57 immunocompromised patients 57 ON #.Na 57 Systemic lupus erythematosus 57 omacetaxine mepesuccinate 57 SinuNase TM 57 Prodarsan R 57 oral FTY# 57 hyperoxaluria 57 ThermoDox R 57 cisplatin gemcitabine 57 dose cohorts 57 Non Hodgkin 57 Motesanib 57 obatoclax 57 metastatic carcinoma 57 lumiliximab 57 iobenguane 57 certolizumab 57 unresectable liver cancer 57 MCyR 57 colorectal pancreatic 57 immunodeficiencies 57 Malignant Melanoma 57 Zenvia ™ 57 investigational compounds 57 somatostatin analogue 57 FOLPI 57 LEP ETU 57 Ibritumomab Tiuxetan 57 VEGF inhibitors 57 dyslipidaemia 57 Actemra tocilizumab 57 Rituxan rituximab 57 EXJADE 57 chronic periodontitis 57 aggressive systemic mastocytosis 57 Voraxaze ™ 57 Etanercept 57 liver transplant recipients 57 Chronic Myelogenous Leukemia CML 57 nonsense mutation 57 allogeneic SCT 57 neutrophil counts 57 Platinol ® 57 ALN PCS 57 paclitaxel poliglumex 57 ribavirin Copegus ® 57 Patients Treated With 57 indolent NHL 56 Akt inhibitor 56 lymphocytic leukemia 56 assessing T DM1 56 topoisomerase II inhibitor 56 Janus Kinase 56 situ CIS 56 imatinib mesylate 56 hypercholesterolaemia 56 curative resection 56 ATACAND 56 sunitinib Sutent ® 56 refractory metastatic colorectal cancer 56 porcine derived 56 Bevacizumab 56 blinatumomab 56 5q deletion 56 Pivotal Trial 56 refractory colorectal cancer 56 Pegylated Liposomal Doxorubicin 56 null responder 56 ZOLINZA 56 eprotirome 56 5 fluorouracil leucovorin 56 virus HCV infection 56 Hematologic 56 Tarceva erlotinib 56 Meets Primary Endpoint 56 TLK# 56 Idiopathic Pulmonary Fibrosis 56 oral JAK1 56 biliary tract cancer 56 unresectable tumors 56 stage IIIB IV 56 Cyclophosphamide 56 Cinryze ™ 56 KRAS mutant 56 TELCYTA 56 BRIM2 56 hypertriglyceridemia 56 gemcitabine cisplatin 56 L MTP PE 56 carcinoid 56 HGS# 56 eosinophilic asthma 56 Trabectedin